Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
ANI Pharmaceuticals Inc(ANIP)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for ANIP
11/06/2026: ANIP (1-star) is currently NOT-A-BUY. Pass it for now.
ANI Pharmaceuticals is a specialty pharmaceutical company focused on rare disease therapies and established prescription products. The firm has successfully transitioned its business model, moving from commodity generics to higher-margin, specialized therapeutic areas, notably with the success of Cortrophin Gel. Its primary growth story is built on a 'buy-and-build' strategy, successfully integrating products into a scalable commercial platform. However, investors must consider the risks of high debt levels, product concentration, and intense competition within the pharmaceutical sector. ANI may suit investors seeking growth-oriented exposure to specialty pharma, though it is a non-dividend paying stock and carries significant execution and regulatory risks.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company is actively scaling its rare disease business and expanding its portfolio through strategic acquisitions. |
| Momentum investor | Mixed fit | Momentum depends on the ongoing successful penetration of Cortrophin Gel and potential positive clinical or acquisition news. |
| Value investor | Mixed fit | Valuation is sensitive to debt levels and the long-term sustainability of margins on core products. |
| Dividend investor | Weak fit | The company does not pay dividends and prioritizes capital reinvestment. |
| Low-risk investor | Weak fit | The pharmaceutical sector, specifically small-cap companies, carries significant regulatory and execution risks. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Small-cap biotech stocks often experience sharp price swings based on news and sector sentiment. |
| Valuation risk | Medium / high | Future growth expectations are baked into the stock price, leaving little room for execution disappointment. |
| Competition risk (specialty generics) | Medium / high | Generic entry in key segments can rapidly erode revenue and margins. |
| Business quality | Medium | While the company has a strong niche strategy, it lacks the massive, diversified moat of large-cap pharma. |
| Dividend income | Low / none | Investors looking for steady income will not find it here. |
| Execution risk | Medium / high | Integrating acquisitions and managing complex supply chains is essential for meeting financial targets. |
Price Behavior
Downtrend
The stock has experienced a sustained decline in price over recent periods.
Smooth
The stock has moved along a generally orderly path with only modest fluctuations.
Analysis of Past Performance
Type Stock | Historic Profit -10.53% | Avg. Invested days 34 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/06/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.53B USD | Price to earnings Ratio 13.4 | 1Y Target Price 105.78 |
Price to earnings Ratio 13.4 | 1Y Target Price 105.78 | ||
Volume (30-day avg) 379.2K shares | Beta 0.47 | 52 Weeks Range 67.14 - 90.87 | Updated Date 11/08/2026 |
52 Weeks Range 67.14 - 90.87 | Updated Date 11/08/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 5.03 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Rare Disease | Includes Cortrophin Gel and related specialized therapeutic treatments. | This is a key high-margin growth area for the company. |
| Generics & Established Brands | A broad portfolio of essential, off-patent pharmaceutical products. | Provides stable, recurring cash flow to support other business areas. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2026-11-05 | When Before Market | Estimate 1.8 | Actual 2.28 |
Profitability
Profit Margin 11.22% | Operating Margin (TTM) 17.83% |
Management Effectiveness
Return on Assets (TTM) 6.41% | Return on Equity (TTM) 20.45% |
Valuation
Trailing PE 13.4 | Forward PE 6.69 | Enterprise Value 1.70B | Price to Sales(TTM) 1.47 |
Enterprise Value 1.70B | Price to Sales(TTM) 1.47 | ||
Enterprise Value to Revenue 1.64 | Enterprise Value to EBITDA 6.67 | Shares Outstanding 22.72M | Shares Floating 19.44M |
Shares Outstanding 22.72M | Shares Floating 19.44M | ||
Percent Insiders 5.37 | Percent Institutions 107.39 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.